Lista de obras -

A systematic methodology review of phase I radiation dose escalation trials

artículo científico publicado en 2010

A systematic review of health economic evaluation in adjuvant breast radiotherapy: Quality counted by numbers

artículo científico publicado en 2017

Access to innovative radiotherapy: how to make it happen from an economic perspective?

artículo científico publicado en 2017

Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction

artículo científico publicado en 2017

Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?

artículo científico publicado en 2017

Automated Instead of Manual Treatment Planning? A Plan Comparison Based on Dose-Volume Statistics and Clinical Preference

artículo científico publicado en 2018

Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients

artículo científico

Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology.

artículo científico

Cost evaluation to optimise radiation therapy implementation in different income settings: A time-driven activity-based analysis

artículo científico publicado en 2017

Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis

artículo científico publicado en 2016

Cost-effectiveness of particle therapy: current evidence and future needs

artículo científico publicado en 2008

Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy

artículo científico publicado en 2008

Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial

artículo científico publicado en 2002

Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study

artículo científico publicado en 2002

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

artículo científico publicado en 2014

Erratum to "Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?" [Crit. Rev. Oncol. Hematol., 119 (November) (2017) 40-49].

artículo científico publicado en 2017

Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis.

artículo científico publicado en 2017

Expanding global access to radiotherapy.

artículo científico

G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy

artículo científico publicado en 2015

Global impact of radiotherapy in oncology: Saving one million lives by 2035.

artículo científico publicado en 2017

Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey

artículo científico

Health Economic Controversy and Cost-Effectiveness of Proton Therapy ⬇️

artículo científico publicado el 1 de abril de 2013

Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation

artículo científico publicado en 2014

Highly Accelerated Irradiation in 5 Fractions (HAI-5): Feasibility in Elderly Women With Early or Locally Advanced Breast Cancer

artículo científico publicado en 2017

How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis

artículo científico publicado en 2016

Hypofractionated breast radiotherapy: financial and economic consequences

scientific article published on June 2010

Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer

artículo científico publicado en 2008

In reply to de Ruysscher et al.

artículo científico publicado en 2014

In search of the economic sustainability of Hadron therapy: the real cost of setting up and operating a Hadron facility

artículo científico publicado en 2014

Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group

artículo científico publicado en 2017

Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

artículo científico publicado en 2006

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

artículo científico publicado en 2014

Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1.

artículo científico

Provision and use of radiotherapy in Europe

scientific article published on 15 April 2020

Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).

artículo científico publicado en 2005

Radiotherapy cost-calculation and its impact on capacity planning

artículo científico publicado en 2003

Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.

artículo científico publicado en 2014

Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey

artículo científico publicado en 2014

Stereotactic body radiotherapy for lung cancer: how much does it really cost?

artículo científico publicado en 2015

Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer.

artículo científico publicado en 2009

Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

artículo científico publicado en 2017

The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.

artículo científico publicado en 2008

The cost of radiotherapy in a decade of technology evolution ⬇️

artículo científico publicado el 26 de agosto de 2011

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.

artículo científico publicado en 2015

The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan.

artículo científico publicado en 2015

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis.

artículo científico publicado en 2015

Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.

artículo científico

Value-based health care - what does it mean for radiotherapy?

artículo científico publicado en 2019

Lista de obras de

A systematic methodology review of phase I radiation dose escalation trials

A systematic review of health economic evaluation in adjuvant breast radiotherapy: Quality counted by numbers

Access to innovative radiotherapy: how to make it happen from an economic perspective?

Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction

Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?

Automated Instead of Manual Treatment Planning? A Plan Comparison Based on Dose-Volume Statistics and Clinical Preference

Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients

Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology.

Cost evaluation to optimise radiation therapy implementation in different income settings: A time-driven activity-based analysis

Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis

Cost-effectiveness of particle therapy: current evidence and future needs

Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy

Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial

Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

Erratum to "Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?" [Crit. Rev. Oncol. Hematol., 119 (November) (2017) 40-49].

Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis.

Expanding global access to radiotherapy.

G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy

Global impact of radiotherapy in oncology: Saving one million lives by 2035.

Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey

Health Economic Controversy and Cost-Effectiveness of Proton Therapy ⬇️

Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation

Highly Accelerated Irradiation in 5 Fractions (HAI-5): Feasibility in Elderly Women With Early or Locally Advanced Breast Cancer

How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis

Hypofractionated breast radiotherapy: financial and economic consequences

Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer

In reply to de Ruysscher et al.

In search of the economic sustainability of Hadron therapy: the real cost of setting up and operating a Hadron facility

Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group

Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: work package 1.

Provision and use of radiotherapy in Europe

Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).

Radiotherapy cost-calculation and its impact on capacity planning

Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.

Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey

Stereotactic body radiotherapy for lung cancer: how much does it really cost?

Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer.

Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?

The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.

The cost of radiotherapy in a decade of technology evolution ⬇️

The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.

The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan.

The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis.

Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.

Value-based health care - what does it mean for radiotherapy?